Comprehensive Stock Comparison
Compare CytomX Therapeutics, Inc. (CTMX) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CTMX | 36.4% revenue growth vs REGN's 1.0% |
| Value | CTMX | Lower P/E (14.1x vs 17.3x) |
| Quality / Margins | REGN | 31.4% net margin vs CTMX's 24.7% |
| Stability / Safety | REGN | Beta 0.58 vs CTMX's 1.08 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; CTMX pays no meaningful dividend |
| Momentum (1Y) | CTMX | +6.9% vs REGN's +12.4% |
| Efficiency (ROA) | CTMX | 17.7% ROA vs REGN's 11.1% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
CytomX Therapeutics is an oncology-focused biopharmaceutical company that develops conditionally activated antibody therapeutics using its proprietary Probody technology platform. It generates revenue primarily through strategic collaborations and licensing deals with major pharmaceutical partners — including AbbVie, Amgen, and Bristol-Myers Squibb — which provide upfront payments, milestone payments, and potential future royalties on any commercialized products. The company's key competitive advantage is its Probody platform technology, which creates conditionally activated therapeutics that remain inactive until they reach the tumor microenvironment, potentially improving safety and efficacy compared to traditional antibody therapies.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CTMX leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). REGN leads in 2 (Financial Metrics, Risk & Volatility).
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 126.2x CTMX's $114M. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to CTMX's 24.7%. On growth, REGN holds the edge at +2.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $114M | $14.3B |
| EBITDAEarnings before interest/tax | $25M | $4.2B |
| Net IncomeAfter-tax profit | $28M | $4.5B |
| Free Cash FlowCash after capex | -$72M | $3.2B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +20.5% | +25.7% |
| Net MarginNet income ÷ Revenue | +24.7% | +31.4% |
| FCF MarginFCF ÷ Revenue | -63.7% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -82.2% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | -2.5% |
Valuation Metrics
At 14.1x trailing earnings, CTMX trades at a 25% valuation discount to REGN's 18.8x P/E. On an enterprise value basis, CTMX's 15.0x EV/EBITDA is more attractive than REGN's 21.6x.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $430M | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $401M | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | 14.13x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x |
| EV / EBITDAEnterprise value multiple | 15.00x | 21.64x |
| Price / SalesMarket cap ÷ Revenue | 3.11x | 7.50x |
| Price / BookPrice ÷ Book value/share | — | 2.72x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x |
Profitability & Efficiency
CTMX delivers a 26.1% return on equity — every $100 of shareholder capital generates $26 in annual profit, vs $14 for REGN. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs CTMX's 4/9, reflecting strong financial health.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | +26.1% | +14.4% |
| ROA (TTM)Return on assets | +17.7% | +11.1% |
| ROICReturn on invested capital | — | +12.4% |
| ROCEReturn on capital employed | +62.0% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 |
| Debt / EquityFinancial leverage | — | 0.09x |
| Net DebtTotal debt minus cash | -$29M | -$16.2B |
| Cash & Equiv.Liquid assets | $38M | $18.9B |
| Total DebtShort + long-term debt | $9M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $6,355 for CTMX. Over the past 12 months, CTMX leads with a +693.0% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors CTMX at 35.7% vs REGN's 1.1% — a key indicator of consistent wealth creation.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +26.4% | +0.8% |
| 1-Year ReturnPast 12 months | +693.0% | +12.4% |
| 3-Year ReturnCumulative with dividends | +149.8% | +3.4% |
| 5-Year ReturnCumulative with dividends | -36.4% | +69.8% |
| 10-Year ReturnCumulative with dividends | -58.4% | +104.7% |
| CAGR (3Y)Annualised 3-year return | +35.7% | +1.1% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than CTMX's 1.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.2% from its 52-week high vs CTMX's 84.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 0.58x |
| 52-Week HighHighest price in past year | $6.35 | $821.11 |
| 52-Week LowLowest price in past year | $0.40 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +84.6% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 52.0 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 687K |
Analyst Outlook
Wall Street rates CTMX as "Buy" and REGN as "Buy". Consensus price targets imply 86.2% upside for CTMX (target: $10) vs 9.7% for REGN (target: $857). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | CTMXCytomX Therapeuti… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.00 | $857.17 |
| # AnalystsCovering analysts | 21 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | 100 | 85.71 | -14.3% |
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs CytomX Therapeutics… (CTMX)'s -36%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | $15M | $138M | +818.1% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -3.9% | 23.1% | +689.4% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| CytomX Therapeutics… (CTMX) | -1.63 | 0.38 | +123.3% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
CytomX Therapeutics, Inc. generated $-87M FCF in 2024 (+28% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
CTMX vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CTMX or REGN a better buy right now?
CytomX Therapeutics, Inc. (CTMX) offers the better valuation at 14.1x trailing P/E, making it the more compelling value choice. Analysts rate CytomX Therapeutics, Inc. (CTMX) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CTMX or REGN?
On trailing P/E, CytomX Therapeutics, Inc. (CTMX) is the cheapest at 14.1x versus Regeneron Pharmaceuticals, Inc. at 18.8x.
03Which is the better long-term investment — CTMX or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -36.4% for CytomX Therapeutics, Inc. (CTMX). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus CTMX's -58.4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CTMX or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus CytomX Therapeutics, Inc.'s 1.08β — meaning CTMX is approximately 87% more volatile than REGN relative to the S&P 500.
05Which has better profit margins — CTMX or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 23.1% for CytomX Therapeutics, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 18.1% for CTMX. At the gross margin level — before operating expenses — CTMX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CTMX or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for CTMX: 86.2% to $10.00.
07Which pays a better dividend — CTMX or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. CTMX does not pay a meaningful dividend and should not be held primarily for income.
08Is CTMX or REGN better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Both have compounded well over 10 years (REGN: +104.7%, CTMX: -58.4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CTMX and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: CTMX is a small-cap deep-value stock; REGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.